Page 43 - 82_01

Hered 1999; 49:139–41.
48. Cho HJ, Xie QW, Calaycay J, Mumford RA, Swiderek
KM, Lee TD, Nathan C. Calmodulin is a subunit of
nitric oxide synthase from macrophages. J Exp Med
1992;176:599–604.
49. Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek
KM, Lee TD, Ding A, Troso T, Nathan C. Cloning
and characterization of inducible nitric oxide synthase
from mouse macrophages. Science 1992; 256:225–28.
50. Shaha AM, MacCarthy PA. Paracrine and autocrine
effects of nitric oxide on myocardial function.
Pharmacology & Therapeutics. 2000: 86 (1), 49–86.
51. Massion PB, O. Dessy FC, Balligand J. -L. Nitric
Oxide and Cardiac Function-Ten Years After, and
Continuing, CirculRes 2003; 93:388-98
52. Andrew PJ, Mayer B. Enzymatic function of nitric
oxide synthases. Cardiovasc Res 1999; 3: 521–31.
53. McDonald KK, Rouhanib R, Handlogtena ME, Blockd
ER, Griffithc OW, Allisona RD, Kilberga MS.
Inhibition of endothelial cell amino acid transport
System y+ by arginine analogs that inhibit nitric oxide
synthase. Biochimica et Biophysica Acta (BBA) –
Biomembranes. 1997; 1324 (1): 133–14;
54. Bonetti PO, Lerman LO, Lerman A. Endothelial
dysfunction: a marker of atherosclerotic risk.
Arterioscler Thromb Vasc Biol 2003; 23:168–75.
55. Flammer AJ, Luscher TF. Three decades of
endothelium research: from the detection of nitric
oxide to the everyday implementation of endothelial
function measurements in cardiovascular diseases.
Swiss Med Wkly2010;140:w13122.
56. RubanyiGM, Romero JC, Vanhoutte PM. Flowinduced
release of endothelium-derived relaxing factor. Am J
Physiol 1986; 250: H1145-H1149.
57. HodgsonJMCB. Marshall JJ. Direct vasoconstriction
and endothelium-dependent vasodilation. Mechanisms
of acetylcholine effects on coronary flow and arterial
diameter in patients with nonstenotic coronary
arteries. Circulation1989;79: 1043-51.
58. ChesterAH, O'neil GS, Tadjkarimi S, PalmerRMJ.
MoncadaS, Yacoub MH. The role of nitric oxide in
mediating endothelium dependent relaxations in the
human epicardial coronary artery. Int. J. Cardiol 1990;
29: 305-9.
59. Chu A, Chambers DE, Lin C-C, Kuehl WD, Palmer
RMJ, Moncada S, Cobb FR. Effects of inhibition of
nitric oxide formation on basal vasomotion and
endotheliumdependent responses of the coronary
arteries in awake dogs. J. Clin. Invest 1991; 87: 1964-
68.
60. Gruetter CA, Gruetter DY, Lyon JE, Kadowitz PJ,
Ignarro LJ. Relationship between cyclic guanosine
3':5'-monophosphate formation and relaxation of
coronary arterial smooth muscle by glyceryl trinitrate,
nitroprusside, nitrite and nitric oxide: effects of
methylene blue and methemoglobin. JPET 1981; 219
(1): 181-6.
42
Godofredo Diéguez Castrillo
61. García JL, Fernández N, García-Villalón AL, Monge
L, Gómez B, Diéguez G. Effects of nitric oxide
synthesis inhibition on the goat coronary circulation
under basal conditions and after vasodilator
stimulation. Br J Pharmacol 1992; 106 (3):563-7.
62. Ignarro LJ, Kadowitz PJ. The pharmacological and
physiological role of cyclic GMP in vascular smooth
muscle relaxation. Annu. Rev. Pharmacol. Toxicol
1985;25: 171-91.
63. GardinerSM, KempPA, BennettT. Effects of N0-nitro-
L-arginine methyl ester on vasodilator responses to
acetylcholine. 5-N-ethylcarboxamidoadenosine or
salbutamol in conscious rats. Br. J.
Pharmacol1991;103: 1725-32.
64. Moncada S, ReesDD, SchulzR, Palmer RMJ.
Development and mechanism of a specific
supersensitivity to nitrovasodilators after inhibition of
vascular nitric oxide synthesis in vivo. Proc. Nati.
Acad. Sci. U. S. A 1991;88: 2166-70
65. Ueeda M, Arroyo IH. OlssonRA. Role of nitric oxide
(N=O) in coronary reactive hyperemia (RH) and the
active hyperemic response to pacing (AG). (Abstract).
The Physiologist1990;33: A-78.
66. Fernández N, Sánchez MA, Martínez MA, García-
Villalón AL, Monge L, Gómez B, Diéguez G. Role of
nitric oxide in vascular tone and in reactivity to
isoproterenol and adenosine in the goat coronary
circulation. Eur J Pharmacol 2000; 387 (1):93-9.
67. Thorin E, Clozel M. The Cardiovascular Physiology
and Pharmacology of Endothelin-1. Adv Pharmacol
2010; 60: 1–26.
68. Mazzuca MQ, Khalil RA. Vascular endothelin receptor
type B: structure, function and dysregulation in
vascular disease Biochem Pharmacol 2012; 15;84
(2):147-62.
69. Vanhoutte PM, Rubanyi GM, Miller VM, Houston DS.
Modulation of vascular smooth muscle contraction by
the endothelium. Annu Rev Physiol 1986;48:307–20.
70. Yanagisawa M, Inoue A, Ishikawa T, Kasuya Y,
Kimura S, Kumagaye S, Nakajima K, Watanabe TX,
Sakakibara S, Goto K, et al. Primary structure,
synthesis, and biological activity of rat endothelin, an
endothelium-derived vasoconstrictor peptide. Proc
Natl Acad Sci USA 1988;85:6964–67.
71. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y,
Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T.
A novel potent vasoconstrictor peptide produced by
vascular endothelial cells. Nature 1988;332:411–15.
72. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S.
Cloning and expression of a cDNA encoding an
endothelin receptor. Nature 1990;348:730–32.
73. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H,
Kimura S, Goto K, Masaki T. Cloning of a cDNA
encoding a non-isopeptide-selective subtype of the
endothelin receptor. Nature 1990;348:732–35.
74. Clozel M, Breu V, Burri K, Cassal JM, Fischli W,
Gray GA, Hirth G, Loffler BM, Muller M, Neidhart
@Real Academia Nacional de Farmacia. Spain